Rx Price Clusters Parallel Managed Care Premiums, AstraZeneca Exec Says

Deeply discounted launch prices for brand name pharmaceuticals are rare because promotional costs are high regardless of price, AstraZeneca Director of Public Policy Robert Freeman, PhD, suggested during the HHS conference on drug pricing Aug. 8 in Washington, D.C.